Side Effects Associated with Liraglutide Treatment for Obesity as Well as Diabetes
Liraglutide is a glucagon-like peptide-1 receptor agonist used as a treatment for type 2 diabetes mellitus, which has been expanded for use at a higher dose in weight control. Therefore, it is necessary to consider adverse reactions of the drug at high doses as well as at lower doses after the indic...
Main Author: | Young-Gyun Seo |
---|---|
Format: | Article |
Language: | English |
Published: |
Korean Society for the Study of Obesity
2021-03-01
|
Series: | Journal of Obesity & Metabolic Syndrome |
Subjects: | |
Online Access: | https://doi.org/10.7570/jomes20059 |
Similar Items
-
Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date
by: Howell R, et al.
Published: (2019-04-01) -
Gglucagon-like peptide-1 analogue liraglutide (Saxenda®): mechanism of action, efficacy for the treatment of obesity
by: Tatiana I. Romantsova
Published: (2018-04-01) -
Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes
by: Inoue Kana, et al.
Published: (2011-12-01) -
Long-Acting Glucagon-Like Peptide-1 Receptor Agonist-Induced Rheumatoid Arthritis in a Patient with Type 2 Diabetes Mellitus
by: Koji Kikkawa, et al.
Published: (2021-09-01) -
Prediction of early response to liraglutide therapy in patients with obesity
by: Oksana V. Logvinova, et al.
Published: (2020-06-01)